Expression of Kinase-defective Mutants of c-Src in Human Metastatic Colon Cancer Cells Decreases Bcl-xL and Increases Oxaliplatin- and Fas-induced Apoptosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Tumor resistance to current drugs prevents curative treatment of human colon cancer. A pressing need for effective, tumor-specific chemotherapies exists. The non-receptor-tyrosine kinase c-Src is overexpressed in >70% of human colon cancers and represents a tractable drug target. KM12L4A human metastatic colon cancer cells were stably transfected with two distinct kinase-defective mutants of c-src. Their response to oxaliplatin, to SN38, the active metabolite of irinotecan (drugs active in colon cancer), and to activation of the death receptor Fas was compared with vector control cells in terms of cell cycle arrest and apoptosis. Both kinase-defective forms of c-Src co-sensitized cells to apoptosis induced by oxaliplatin and Fas activation but not by SN38. Cells harboring kinase-defective forms of c-Src carrying function blocking point mutations in SH3 or SH2 domains were similarly sensitive to oxaliplatin, suggesting that reduction in kinase activity and not a Src SH2-SH3 scaffold function was responsible for the observed altered sensitivity. Oxaliplatin-induced apoptosis, potentiated by kinase-defective c-Src mutants, was dependent on activation of caspase 8 and associated with Bid cleavage. Each of the stable cell lines in which kinase-defective mutants of c-Src were expressed had reduced levels of Bcl-x(L.) However, inhibition of c-Src kinase activity by PP2 in vector control cells did not alter the oxaliplatin response over 72 h nor did it reduce Bcl-x(L) levels. The data suggest that longer term suppression of Src kinase activity may be required to lower Bcl-x(L) levels and sensitize colon cancer cells to oxaliplatin-induced apoptosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, evidence from preclinical studies in sarcoma and ovarian cancer cell lines suggests that activation of Src reduces sensitivity to various chemotherapeutic drugs, including platinum agents, and that this resistance can be reversed by pharmacological inhibition [19, 20][21–23][24].”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [21]
In the citing paper
“Moreover, expression of a dominant negative, kinase-defective Src mutant resulted in increased sensitivity to oxaliplatin-mediated apoptosis in KM12L4 human colon tumor cells in vitro [21].”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [21]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A. P., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D. A., & Boyd, M. R. (1988) · PubMed · Cited by 2,737
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Src in cancer: deregulation and consequences for cell behaviour
Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 683
Self-citationStat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation
Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., & Jove, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2545 · Cited by 651
Pelengaris, S., Khan, M., & Evan, G. I. (2002) · Cell · doi:10.1016/s0092-8674(02)00738-9 · Cited by 626
Stat3 Activation Is Required for Cellular Transformation by v- src
Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., & Darnell, J. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2553 · Cited by 614
Martin, G. S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35073094 · Cited by 599
Activating SRC mutation in a subset of advanced human colon cancers
Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489
Flow Cytometry: A Practical Approach
Ormerod, M. G. (1994) · Cited by 452
Research works printed but not linked: 7
- Frame, 2002, Biochim. Biophys. Acta, 1602, 114
- Cam, 2001, Cancer, 92, 61, 10.1002/1097-0142(20010701)92:1<61::aid-cncr1292>3.0.co;2-d · DOI · Paper page
- Scudiero, 1988, Cancer Res., 48, 4827
- Kinoshita, 2000, Int. J. Cancer, 88, 986, 10.1002/1097-0215(20001215)88:6<986::aid-ijc23>3.0.co;2-b · DOI · Paper page
- Tillman, 1999, Clin. Cancer Res., 5, 425
- Morikawa, 1988, Cancer Res., 48, 1943
- Masumoto, 1999, Int. J. Cancer, 80, 731, 10.1002/(sici)1097-0215(19990301)80:5<731::aid-ijc17>3.0.co;2-h · doi:10.1002/(sici)1097-0215(19990301)80:5<731::aid-ijc17>3.0.co;2-h
Cited by
Targeting Src in breast cancer
Finn, R. S. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn291 · Cited by 248
“Src inhibition has also been shown to augment the therapeutic effects of cytotoxic chemotherapy drugs in vitro [70, 71].”
BackgroundShakibaei, M., Mobasheri, A., Lueders, C., Busch, F., Shayan, P., & Goel, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057218 · Cited by 226
“Indeed, it has been reported that suppression of Src signaling sensitizes tumor cells to chemotherapies [56,57].”
BackgroundSrc kinase phosphorylates Caspase‐8 on Tyr380: a novel mechanism of apoptosis suppression
Cursi, S., Rufini, A., Stagni, V., Condò, I., Matafora, V., Bachi, A., Bonifazi, A. P., Coppola, L., Superti‐Furga, G., Testi, R., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601085 · Cited by 205
“Interestingly, inhibition of Src sensitizes human colon cancer cell lines to Fas-induced apoptosis (Griffiths et al, 2004).”
BackgroundKopetz, S., Lesslie, D. P., Dallas, N. A., Park, S. I., Johnson, M., Parikh, N. U., Kim, M. P., Abbruzzese, J. L., Ellis, L. M., Chandra, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2246 · Cited by 160
“Our data imply that the combination of dasatinib and oxaliplatin will not affect all colon tumor cells, as also shown by others (15).”
Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells
Nautiyal, J., Kanwar, S. S., Yu, Y., & Majumdar, A. P. N. (2011) · Journal of Molecular Signaling · doi:10.1186/1750-2187-6-7 · Cited by 146
“Pre-clinical evidence indicates that inhibition of Src renders the cancer cells susceptible to chemotherapies [44-46].”
BackgroundThe Role of Src in Colon Cancer and Its Therapeutic Implications
Chen, J., Elfiky, A. A., Han, M., Chen, C., & Saif, M. W. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.10.003 · Cited by 141
“In the metastatic human colon cancer cell line KM12L4A, transfection of 2 mutant forms of Src, with a point mutation in SH2 or SH3, increases the sensitivity of the cancer cells to oxaliplatin.(105) A recent study showed that leptin, a stimulator of Src that is expressed at increased levels in obese persons, decreased…”
BackgroundWilson, C., Purcell, C., Seaton, A., Oladipo, O., Maxwell, P. J., O’Sullivan, J. M., Wilson, R. H., Johnston, P. G., & Waugh, D. J. J. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143826 · Cited by 127
“Prior studies have shown that oxaliplatin induces apoptosis in colorectal cancer cells through the activation of caspase-8 and Bid cleavage, suggesting a role for the extrinsic apoptosis pathway (Griffiths et al., 2004; Longley et al., 2006).”
BackgroundSrc continues aging: current and future clinical directions
Kopetz, S., Shah, A. N., & Gallick, G. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1902 · Cited by 111
Chen, T., Pengetnze, Y., & Taylor, C. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.217.4.2 · Cited by 101
Xie, T., Huang, M., Wang, Y., Wang, L., Chen, C., & Chu, X. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000452525 · Cited by 90
The Src Family of Protein Tyrosine Kinases: A New and Promising Target for Colorectal Cancer Therapy
Lieu, C., & Kopetz, S. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.012 · Cited by 86
Src family kinases and paclitaxel sensitivity
Le, X.-F., & Bast, Jr. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.16430 · Cited by 79
Martínez‐Cardús, A., Martinez‐Balibrea, E., Bandrés, E., Malumbres, R., Ginés, A., Manzano, J. L., Tarón, M., García‐Foncillas, J., & Abad, A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0659 · Cited by 73
Parseghian, C. M., Parikh, N. U., Wu, J. Y., Jiang, Z.-Q., Henderson, L., Tian, F., Pastor, B., Ychou, M., Raghav, K., Dasari, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3138 · Cited by 67
“Colon cancer cell lineswithdefective Src kinases are particularly sensitive to oxaliplatin-induced apoptosis (16).”
BackgroundMamidipudi, V., & Cartwright, C. A. (2009) · Oncogene · doi:10.1038/onc.2009.293 · Cited by 66
“When KM12L4A metastatic colon cancer cells were transfected with two distinct kinase-defective mutants of Src, both co-sensitized cells to apoptosis induced by Oxaliplatin and Fas activation, in part by activation of caspase-8 and Bid and inhibition of Bcl-XL (Griffiths et al., 2004).”
BackgroundYamamoto, N., Mammadova, G., Song, R. X.-D., Fukami, Y., & Sato, K. (2006) · Journal of Cell Science · doi:10.1242/jcs.03236 · Cited by 60
“For example, a recent report by Murillo et al. (Murillo et al., 2005) has shown that TGF 1-induced survival of hepatocytes require EGFR and Src, and Griffiths et al. (Griffiths et al., 2004) have shown that kinase-inactive mutants of Src increase Fas-induced apoptosis in colon cancer cells.”
BackgroundWatzlawik, J. O., Holicky, E. L., Edberg, D. D., Marks, D. L., Warrington, A. E., Wright, B. R., Pagano, R. E., & Rodriguez, M. (2010) · Glia · doi:10.1002/glia.21048 · Cited by 59
“PP2 and SU6656 are widely used as selective SFK inhibitors (Bain et al., 2003, 2007; Blake et al., 2000) and have been shown to be effective in many cell types including OLs (Chudakova et al., 2008; Contri et al., 2005; Golubovskaya et al., 2003; Griffiths et al., 2004; Park et al., 2004).”
BackgroundSrc, chemoresistance and epithelial to mesenchymal transition: are they related?
Shah, A. N., & Gallick, G. E. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32801265d7 · Cited by 54
The Src Inhibitor AZD0530 Blocks Invasion and May Act as a Radiosensitizer in Lung Cancer Cells
Purnell, P. R., Mack, P. C., Tepper, C. G., Evans, C. P., Green, T. P., Gumerlock, P. H., Lara, P. N., Gandara, D. R., Kung, H.-J., & Gautschi, O. P. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819c78fb · Cited by 59
Yuan, K., Gu, J., Chen, J., Liu, H., Zhang, K., Li, Y., Wu, H., McDonald, J. M., & Chen, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.202804 · Cited by 57
Oxaliplatin Induced Suicidal Death of Human Erythrocytes
Fazio, A., Briglia, M., Faggio, C., Alzoubi, K., & Lang, F. J. W. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000438592 · Cited by 51
Reddy, S. M., Kopetz, S., Morris, J., Parikh, N., Qiao, W., Overman, M. J., Fogelman, D., Shureiqi, I., Jacobs, C., Malik, Z., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0257-z · Cited by 45
Zhang, Y., Cheng, Y., Zhang, L., Ren, X., Huber-Keener, K. J., Lee, S. Y., Yun, J. K., Wang, H., & Yang, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.09.038 · Cited by 40
“Bcl-xL resides within the mitochondrial membrane where it acts by inhibiting adaptor molecules needed for activation of the effector caspases [17], and is known to suppress apoptosis induced by TRAIL [18, 19, 20] and some other therapeutic insults [21].”
BackgroundColorectal carcinoma: from tumorigenesis to treatment
Wang, W. S., Chen, P. M., & Su, Y. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5425-4 · Cited by 40
Bionda, C., Athias, A., Poncet, D., Alphonse, G., Guezguez, A., Gambert, P., Rodriguez‐Lafrasse, C., & Ardail, D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.10.004 · Cited by 37
(2007) · PubMed
Perez, M., Lucena-Cacace, A., Marín-Gómez, L. M., Padillo-Ruiz, J., Robles-Frias, M. J., Saez, C., Garcia-Carbonero, R., & Carnero, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8880 · Cited by 34
“Moreover, expression of a dominant negative, kinase-defective Src mutant resulted in increased sensitivity to oxaliplatin-mediated apoptosis in KM12L4 human colon tumor cells in vitro [21].”
Mitchell, C., Kabolizadeh, P., Ryan, J., Roberts, J. D., Yacoub, A., Curiel, D. T., Fisher, P. B., Hagan, M. P., Farrell, N. P., Grant, S., et al. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.038406 · Cited by 32
“In a variety of colon cancer cell lines, oxaliplatin has been shown to promote predominantly activation of the extrinsic or, to a lesser extent, intrinsic apoptosis pathways (Arango et al., 2004; Griffiths et al., 2004; Galligan et al., 2005; McDermott et al., 2005; Longley et al., 2006).”
BackgroundIntegrin β3-mediated Src activation regulates apoptosis in IEC-6 cells via Akt and STAT3
Bhattacharya, S., Ray, R. M., & Johnson, L. R. (2006) · Biochemical Journal · doi:10.1042/bj20060256 · Cited by 31
Zhang, W., Pan, R., Lu, M., Zhang, Q., Lin, Z., Qin, Y., Wang, Z., Gong, S., Lin, H., Chong, S., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02029-4 · Cited by 31
Toni, E. N. D., Kuntzen, C., Gerbes, A. L., Thasler, W. E., Sonuc, N., Mucha, S. R., Čamaj, P., Bruns, C. J., Göke, B., & Eichhorst, S. T. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.10.010 · Cited by 30
Strickler, J. H., McCall, S. J., Nixon, A. B., Brady, J. C., Pang, H., Rushing, C. N., Cohn, A. L., Starodub, A., Arrowood, C., Haley, S. T., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0042-9 · Cited by 27
“Src activation is implicated in chemotherapy resistance, and preclinical studies support the role of src inhibitors in restoring sensitivity to 5-FU and platinum-based chemotherapy [5, 11, 16].”
DNA damage induced by novel demethylcantharidin-integrated platinum anticancer complexes
Pang, S.-K., Yu, C., Au‐Yeung, S. C. F., & Ho, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.172 · Cited by 27
Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells
Shi, M., Lou, B.-X., Ji, J., Shi, H., Zhou, C., Yu, Y., Liu, B., Zhu, Z., & Zhang, J. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2166-1 · Cited by 22
“human colon tumor cells in vitro, which indicate that Src inhibition could be a valuable addition to oxaliplatin-based regimens [29].”
BackgroundPrognostic relevance of Src activation in stage II-III colon cancer
Martínez-Pérez, J., Lopez-Calderero, I., Saez, C., Benavent, M., Limon, M. L., Gonzalez-Exposito, R., Soldevilla, B., Riesco-Martínez, M. C., Salamanca, J., Carnero, A., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.05.025 · Cited by 20
Shimada, Y., Muneoka, Y., Nagahashi, M., Ichikawa, H., Tajima, Y., Hirose, Y., Ando, T., Nakano, M., Sakata, J., Kameyama, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39328-6 · Cited by 19
Kopetz, S., Morris, V. K., Parikh, N. U., Overman, M. J., Jiang, Z.-Q., Maru, D. M., Elvin, P., & Gallick, G. E. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-660 · Cited by 19
“In vivo studies for multiple solid tumors have demonstrated that Src activity is implicated in resistance to chemotherapy and that inhibition of Src may restore sensitivity to chemotherapy [14-16].”
BackgroundKline, C. L. B., & Irby, R. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0648-3 · Cited by 17
SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling
Souza, V., Dong, Y., Zhou, H., Zacharias, W., & McMasters, K. M. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-44 · Cited by 17
Maślikowski, B. M., Néel, B., Wu, Y., Wang, L., Rodrigues, N., Gillet, G., & Bédard, P. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-41 · Cited by 18
Jarvis, I. W. H., Meczes, E. L., Thomas, H. D., Edmondson, R. J., Veal, G. J., Boddy, A. V., Ottley, C. J., Pearson, D. G., & Tilby, M. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.10.005 · Cited by 14
Self-citationThe Crosstalk of Apoptotic and Non-Apoptotic Signaling in CD95 System
Seyrek, K., Espe, J., Reiss, E., & Lavrik, I. N. (2024) · Cells · doi:10.3390/cells13211814 · Cited by 13
Feng, X., Huang, S., Shou, J., Liao, B., Yingling, J. M., Ye, X., Lin, X., Gelbert, L. M., Su, E. W., Onyia, J. E., et al. (2007) · Genomics Proteomics & Bioinformatics · doi:10.1016/s1672-0229(07)60010-2 · Cited by 13
Pharmacogenomics in colorectal carcinomas: Future perspectives in personalized therapy
Russo, A. D., Corsale, S., Cammareri, P., Agnese, V., Cascio, S., Fede, G. D., Macaluso, M., & Bazan, V. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20357 · Cited by 13
“Irinotecan and SN-38 bind to the topoisomerase DNA complex preventing religation of the singlestrand breaks in the DNA molecule and causing DNA double strand breaks, which can lead to apoptosis (Catley et al., 2004; Griffiths et al., 2004).”
BackgroundEmerging drugs for colorectal cancer
Fogelman, D. R., Kopetz, S., & Eng, C. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802544575 · Cited by 10
“However, Src has been implicated in the development of resistance to cetuximab [68,69] , and inhibition of Src sensitizes tumors to cytotoxic chemotherapy, including oxaliplatin [70] .”
BackgroundDeli, H., Vakili-Ghartavol, Z., Asgari, Y., Tavoosidana, G., Eftekhar, E., & Ghahremani, M. H. (2025) · BMC Cancer · doi:10.1186/s12885-024-13392-2 · Cited by 10
Vojtěchová, M., Šenigl, F., Šloncová, E., & Tuháčková, Z. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.09.011 · Cited by 7
Src Inhibition Is Still a Relevant Target in Pancreatic Cancer
George, T. J., Trevino, J. G., & Liu, C. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0410 · Cited by 7
Colorectal Cancer Therapeutics and the Challenges of Applied Pharmacogenomics
Kruzelock, R. P., & Short, W. (2007) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2007.05.001 · Cited by 6
Davis, T. B., Gupta, S., Yang, M., Pflieger, L. T., Rajan, M., Wang, H., Thota, R., Yeatman, T. J., & Pledger, W. J. (2022) · Cancers · doi:10.3390/cancers14061451 · Cited by 4
“In vivo studies for multiple solid tumors have demonstrated that SRC activity may also be responsible for resistance to chemotherapy [22,23].”
BackgroundDynamic Regulation of Adherens Junctions: Implication in Cell Differentiation and Tumor Development
Pelissier-Rota, M. A., Chartier, N. T., & Jacquier‐Sarlin, M. R. (2015) · Springer eBooks · doi:10.1007/978-94-017-7380-5_4 · Cited by 3
Structural basis of constitutive c-Src kinase activity due to R175L and W118A mutations
Gul, M., Ahmad, N., & Rashid, S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2010600 · Cited by 3
“Multiple lines of evidence suggest that any imbalance in the c-Src activity results in cancer ( Boczek et al., 2019; Griffiths et al., 2004; Roskoski, 2015 ).”
BackgroundMethodInfluentialHorak, C. E., Bronder, J. L., Bouadis, A., & Steeg, P. S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-200-7_3 · Cited by 2
Stool and Blood Sampling for Early Detection of Colorectal Cancer
Sicklick, J. K., & Ahuja, N. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4686-8.50014-2 · Cited by 1
A Role For Lipid Rafts In Egfr Tki Resistance In Breast Cancer
Irwin, M. E. (2010) · Human Biology
Kopetz, S., Lesslie, D. P., Dallas, N. A., Park, S. I., Johnson, M., Parikh, N. U., Kim, M. P., Abbruzzese, J. L., Ellis, L. M., Chandra, J., et al. (2023) · doi:10.1158/0008-5472.c.6499370.v1
Nonreceptor Tyrosine Kinases and Their Roles in Cancer
Wiener, J. R., & Gallick, G. E. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1216-8_4
The role of tyrosine phosphorylation in modulating death receptor signaling
Dilsiz, P., & Hapil, F. Z. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.07.005
Pelissier-Rota, M. A. (2014) · theses.fr (ABES) · doi:10.70675/034352caz38ffz4bd5za0eczec6c0490ea78
Development of novel therapies for colorectal carcinoma using dietary indoles
Brookes, A. (2014) · Figshare
Metadata
- Authors
- Griffiths, G. J., Koh, M. Y., Brunton, V. G., Cawthorne, C., Reeves, N. A., Greaves, M., Tilby, M. J., Pearson, D. G., Ottley, C. J., Workman, P., Frame, M. C., & Dive, C.
- Affiliations
- Cancer Research UK (GB)
- Newcastle University (GB)
- Durham University (GB)
- Institute of Cancer Research (GB)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Dive, Caroline
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 279
- Issue
- 44
- Pages
- 46113-46121
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2136103100
- Cited by
- 60
- References
- 48
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2019: 1 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 4
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5832 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Durham Research Online (Durham University) (acceptedVersion)
- Durham Research Online (Durham University) (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- Src kinase, colon cancer, metastatic colon cancer, oxaliplatin, Fas-mediated apoptosis, Bcl-xL, SN-38, irinotecan, caspase-8, Bid cleavage, apoptosis sensitization, SH2 domain, SH3 domain, PP2, non-receptor tyrosine kinase, drug resistance
- MeSH terms
- Oxaliplatin, CSK Tyrosine-Protein Kinase, Colonic Neoplasms, Humans, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Protein-Tyrosine Kinases, Pyrimidines, Apoptosis, fas Receptor, src-Family Kinases, Proto-Oncogene Proteins c-bcl-2, Caspases, Cell Line, Tumor, bcl-X Protein, Caspase 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.